Based on these preclinical research findings, a phase II clinical trial (NCT04620330) is currently underway (Capelletto et al., 2022) to investigate the true efficacy of the combination therapy of FAK inhibitor defactinib and the RAF/MEK inhibitor VS-6766 for KRAS-mutant NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.